Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Simone Borgoni

5PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

Sort by Publication Date:
|Apr 29, 2026
GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

|Jul 27, 2022
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.

Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee

|May 04, 2021
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.

Yuya Haga, Ilaria Marrocco, Ashish Noronha

|Dec 15, 2020
Extracellular Vesicles Orchestrate Immune and Tumor Interaction Networks.

Kevin Ho Wai Yim, Ala'a Al Hrout, Simone Borgoni

|Oct 14, 2020
Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer.

Simone Borgoni, Emre Sofyalı, Maryam Soleimani

Pageof 1

Frequent Collaborators

4 joint publications

Stefan Wiemann

3 joint publications

Rainer Will

3 joint publications

Nishanth Belugali Nataraj

2 joint publications

Arunachalam Sekar

2 joint publications

Yosef Yarden

2 joint publications

Moshe Oren

1 joint publications

Pernette J Verschure

1 joint publications

Cindy Körner

1 joint publications

Richard Chahwan

1 joint publications

Mary Luz Uribe

Frequent Collaborators

4 joint publications

Stefan Wiemann

3 joint publications

Rainer Will

3 joint publications

Nishanth Belugali Nataraj

2 joint publications

Arunachalam Sekar

Top Related Videos

Site-Specific Lysine Lactylation via Genetic Code Expansion in <em>E. coli </em>and Mammalian Cells
05:58

Site-Specific Lysine Lactylation via Genetic Code Expansion in <em>E. coli </em>and Mammalian Cells

Published on : Feb 24, 2026

684
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

9.0K
See more related videos

Top Related Videos

Site-Specific Lysine Lactylation via Genetic Code Expansion in <em>E. coli </em>and Mammalian Cells
05:58

Site-Specific Lysine Lactylation via Genetic Code Expansion in <em>E. coli </em>and Mammalian Cells

Published on : Feb 24, 2026

684
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

9.0K
See more related videos